Protein aggregation diseases: pathogenicity and therapeutic perspectives.

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68

Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature (2011) 4.56

The amyloid state of proteins in human diseases. Cell (2012) 4.53

A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol (2015) 2.53

Prions in yeast. Genetics (2012) 2.04

Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71

Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66

Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One (2010) 1.62

Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. J Chem Phys (2011) 1.52

A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem (2011) 1.48

Is AD a homogeneous nosologic entity? Yes. J Neural Transm (Vienna) (2013) 1.39

Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (2012) 1.38

Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates. J Cell Sci (2012) 1.30

Destabilization and recovery of a yeast prion after mild heat shock. J Mol Biol (2011) 1.27

Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Proc Natl Acad Sci U S A (2014) 1.25

Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat Chem (2012) 1.16

The elusive middle domain of Hsp104 and ClpB: location and function. Biochim Biophys Acta (2011) 1.09

Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06

Localization of HET-S to the cell periphery, not to [Het-s] aggregates, is associated with [Het-s]-HET-S toxicity. Mol Cell Biol (2011) 1.03

Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia. PLoS One (2013) 1.00

Prion protein in Alzheimer's pathogenesis: a hot and controversial issue. EMBO Mol Med (2010) 1.00

RNAi medicine for the brain: progresses and challenges. Hum Mol Genet (2011) 1.00

Thinking laterally about neurodegenerative proteinopathies. J Clin Invest (2013) 0.99

Parallel β-sheet vibrational couplings revealed by 2D IR spectroscopy of an isotopically labeled macrocycle: quantitative benchmark for the interpretation of amyloid and protein infrared spectra. J Am Chem Soc (2012) 0.99

Physiological and environmental control of yeast prions. FEMS Microbiol Rev (2013) 0.97

Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Sträussler-Scheinker disease. J Neurosci (2012) 0.96

NSAID-based γ-secretase modulators do not bind to the amyloid-β polypeptide. Biochemistry (2011) 0.96

Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations. J Chem Phys (2011) 0.96

Acquisition of drug resistance and dependence by prions. PLoS Pathog (2013) 0.96

Toward quantitative "in vivo biochemistry" with fluorescence fluctuation spectroscopy. Mol Biol Cell (2010) 0.94

Propensity to form amyloid fibrils is encoded as excitations in the free energy landscape of monomeric proteins. J Mol Biol (2014) 0.90

Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands. J Biol Chem (2012) 0.90

Structure and dynamics of oligomeric intermediates in β2-microglobulin self-assembly. Biophys J (2011) 0.88

Effect of the Tottori familial disease mutation (D7N) on the monomers and dimers of Aβ40 and Aβ42. ACS Chem Neurosci (2013) 0.88

Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches. PLoS One (2014) 0.88

Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. EMBO J (2017) 0.87

Development of dual inhibitors against Alzheimer's disease using fragment-based QSAR and molecular docking. Biomed Res Int (2014) 0.87

Effect of sequence variation on the mechanical response of amyloid fibrils probed by steered molecular dynamics simulation. Biophys J (2012) 0.86

Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant. Int J Nanomedicine (2015) 0.85

p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene (2014) 0.84

Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem (2013) 0.84

Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions. J Virol (2011) 0.84

Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci U S A (2014) 0.84

Effect of the English familial disease mutation (H6R) on the monomers and dimers of Aβ40 and Aβ42. ACS Chem Neurosci (2014) 0.83

Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer's disease. J Biomed Biotechnol (2010) 0.82

Chemical probes that selectively recognize the earliest Aβ oligomers in complex mixtures. J Am Chem Soc (2010) 0.82

Thermal stabilization of dihydrofolate reductase using monte carlo unfolding simulations and its functional consequences. PLoS Comput Biol (2015) 0.81

The role of the NADPH oxidase NOX2 in prion pathogenesis. PLoS Pathog (2014) 0.81

Molten globule of hemoglobin proceeds into aggregates and advanced glycated end products. PLoS One (2013) 0.81

Striatal pathology underlies prion infection-mediated hyperactivity in mice. Prion (2010) 0.81

Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines (2010) 0.80

Ischemic postconditioning protects neuronal death caused by cerebral ischemia and reperfusion via attenuating protein aggregation. Int J Med Sci (2012) 0.80

Differential Toxicity of Antibodies to the Prion Protein. PLoS Pathog (2016) 0.80

Cu, Zn-superoxide dismutase 1 (SOD1) is a novel target of Puromycin-sensitive aminopeptidase (PSA/NPEPPS): PSA/NPEPPS is a possible modifier of amyotrophic lateral sclerosis. Mol Neurodegener (2011) 0.80

Cryptic Amyloidogenic Elements in the 3' UTRs of Neurofilament Genes Trigger Axonal Neuropathy. Am J Hum Genet (2016) 0.79

Preeclampsia and health risks later in life: an immunological link. Semin Immunopathol (2016) 0.79

Homodimerization as a molecular switch between low and high efficiency PrP C cell surface delivery and neuroprotective activity. Prion (2013) 0.79

Optineurin: The autophagy connection. Exp Eye Res (2015) 0.78

Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. Antioxid Redox Signal (2014) 0.78

Helices 2 and 3 are the initiation sites in the PrP(C) → PrP(SC) transition. Biochemistry (2012) 0.78

Discovery of dihydrochalcone as potential lead for Alzheimer's disease: in silico and in vitro study. PLoS One (2013) 0.78

Mdm20 stimulates polyQ aggregation via inhibiting autophagy through Akt-Ser473 phosphorylation. PLoS One (2013) 0.78

A peptide that binds specifically to the β-amyloid of Alzheimer's disease: selection and assessment of anti-β-amyloid neurotoxic effects. PLoS One (2011) 0.78

The frequency of yeast [PSI(+)] prion formation is increased during chronological ageing. Microb Cell (2017) 0.77

Eugenol prevents amyloid formation of proteins and inhibits amyloid-induced hemolysis. Sci Rep (2017) 0.77

Extension of the generic amyloid hypothesis to nonproteinaceous metabolite assemblies. Sci Adv (2015) 0.77

Early behavioral changes and quantitative analysis of neuropathological features in murine prion disease: stereological analysis in the albino Swiss mice model. Prion (2011) 0.77

Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide. J Biol Chem (2015) 0.76

Two-steps control of cellular prion physiology by the extracellular regulated kinase-1 (ERK1). Prion (2012) 0.76

Ubiquitous amyloids. Appl Biochem Biotechnol (2012) 0.76

The extracellular chaperone haptoglobin prevents serum fatty acid-promoted amyloid fibril formation of β2-microglobulin, resistance to lysosomal degradation, and cytotoxicity. J Biol Chem (2013) 0.76

ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol (2017) 0.75

A precursor-inducible zebrafish model of acute protoporphyria with hepatic protein aggregation and multiorganelle stress. FASEB J (2016) 0.75

Alzheimer's disease: the silver tsunami of the 21(st) century. Neural Regen Res (2016) 0.75

Ubiquitin ligase ITCH recruitment suppresses the aggregation and cellular toxicity of cytoplasmic misfolded proteins. Sci Rep (2014) 0.75

Protein aggregation into insoluble deposits protects from oxidative stress. Redox Biol (2017) 0.75

Disaggregation of Amylin Aggregate by Novel Conformationally Restricted Aminobenzoic Acid containing α/β and α/γ Hybrid Peptidomimetics. Sci Rep (2017) 0.75

Preventing peptide and protein misbehavior. Proc Natl Acad Sci U S A (2015) 0.75

Bilateral recurrent facial primary cutaneous nodular amyloidosis (PCNA). JAAD Case Rep (2016) 0.75

Native Electrophoresis-Coupled Activity Assays Reveal Catalytically-Active Protein Aggregates of Escherichia coli β-Glucuronidase. PLoS One (2015) 0.75

Fluorescence Self-Quenching from Reporter Dyes Informs on the Structural Properties of Amyloid Clusters Formed in Vitro and in Cells. Nano Lett (2016) 0.75

Analysis of [SWI(+) ] Formation and Propagation Events. Mol Microbiol (2016) 0.75

Kinetics of Protein Complex Dissociation Studied by Hydrogen/Deuterium Exchange and Mass Spectrometry. Anal Chem (2015) 0.75

Effects of intramolecular distance between amyloidogenic domains on amyloid aggregation. Int J Mol Sci (2012) 0.75

Fate of microglia during HIV-1 infection: From activation to senescence? Glia (2016) 0.75

p62/Sequestosome-1 Is Indispensable for Maturation and Stabilization of Mallory-Denk Bodies. PLoS One (2016) 0.75

Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein. Sci Rep (2016) 0.75

Structural Basis for Carbohydrate Recognition and Anti-inflammatory Modulation by Gastrointestinal Nematode Parasite Toxascaris leonina Galectin. J Biol Chem (2016) 0.75

Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood. Mol Immunol (2014) 0.75

Time-dependent X-ray diffraction studies on urea/hen egg white lysozyme complexes reveal structural changes that indicate onset of denaturation. Sci Rep (2016) 0.75

Discovery of DNA dyes Hoechst 34580 and 33342 as good candidates for inhibiting amyloid beta formation: in silico and in vitro study. J Comput Aided Mol Des (2016) 0.75

A Turkish Family with a Familial ALS-positive UBQLN2-S340I Mutation. Noro Psikiyatr Ars (2016) 0.75

β-Hairpin mimics containing a piperidine-pyrrolidine scaffold modulate the β-amyloid aggregation process preserving the monomer species. Chem Sci (2016) 0.75

The San1 Ubiquitin Ligase Functions Preferentially with Ubiquitin-conjugating Enzyme Ubc1 during Protein Quality Control. J Biol Chem (2016) 0.75

Chronic Progressive Neurodegeneration in a Transgenic Mouse Model of Prion Disease. Front Neurosci (2016) 0.75

Protein quality control in the nucleus. Curr Opin Cell Biol (2016) 0.75

Strain conformation controls the specificity of cross-species prion transmission in the yeast model. Prion (2016) 0.75

Multisite aggregation of p53 and implications for drug rescue. Proc Natl Acad Sci U S A (2017) 0.75

Kinetic Monte Carlo simulations of the assembly of filamentous biomacromolecules by dimer addition mechanism. RSC Adv (2015) 0.75

Unrestrained AMPylation targets cytosolic chaperones and activates the heat shock response. Proc Natl Acad Sci U S A (2016) 0.75

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09

A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19

Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36

Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature (2007) 10.02

Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol (1998) 8.91

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89

3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A (2005) 8.60

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40

Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 8.31

Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 7.59

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 6.62

Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52

Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77

Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60

Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science (2005) 5.52

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature (1999) 5.48

Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80

Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem (1999) 4.64

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 4.62

Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 4.57

Plaques, tangles and dementia. A quantitative study. J Neurol Sci (1982) 4.52

Skeletal and CNS defects in Presenilin-1-deficient mice. Cell (1997) 4.50

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45

Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med (2005) 4.42

The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci (2008) 4.28

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27

Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature (1996) 4.25

Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med (1998) 4.17

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10

Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98

Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85

Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci (2006) 3.85

Intraneuronal Abeta42 accumulation in human brain. Am J Pathol (2000) 3.83

Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77

Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell (1998) 3.59

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A (2001) 3.39

The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry (2000) 3.31

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci (2005) 3.23

A crucial role for B cells in neuroinvasive scrapie. Nature (1998) 3.19

Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14

Molecular mechanisms of prion pathogenesis. Annu Rev Pathol (2008) 3.05

Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron (2008) 2.99

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A (2000) 2.96

Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab (2004) 2.92

BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 2.90

The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A (2008) 2.82

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71

Signals determining protein tyrosine kinase and glycosyl-phosphatidylinositol-anchored protein targeting to a glycolipid-enriched membrane fraction. Mol Cell Biol (1994) 2.70

Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem (1995) 2.68

Prion strain discrimination using luminescent conjugated polymers. Nat Methods (2007) 2.62

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol (2008) 2.62

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50

gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med (2005) 2.43

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci (2002) 2.42

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol (2009) 2.41

The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science (2009) 2.35

Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J (2003) 2.34

Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 2.31

Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28

Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J (2007) 2.27

A systematic review of prion therapeutics in experimental models. Brain (2006) 2.25

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) 2.24

Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem (2007) 2.22

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21

BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol (2007) 2.18

Differential sorting and fate of endocytosed GPI-anchored proteins. EMBO J (2002) 2.15

Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15

beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem (2005) 2.15

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15

Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science (2000) 2.15

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12

Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J Cell Biol (2003) 2.12

Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J (2007) 2.12

The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem (2005) 2.08

Chronic lymphocytic inflammation specifies the organ tropism of prions. Science (2005) 2.07

Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med (2004) 2.02

Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 2.00

The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem (2003) 1.99

Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol (2004) 1.97

Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci (2009) 1.88

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med (1996) 1.86

The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans (2005) 1.84

Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci (2007) 2.49

Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci (2005) 1.76

The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature (2013) 1.27

The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation (2011) 1.26

Ablation of Dicer from murine Schwann cells increases their proliferation while blocking myelination. PLoS One (2010) 1.07

The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol (2015) 0.94

ZyFISH: a simple, rapid and reliable zygosity assay for transgenic mice. PLoS One (2012) 0.86

CCL2-CCR2 Signaling in Disease Pathogenesis. Endocr Metab Immune Disord Drug Targets (2015) 0.85

Correction: Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways. PLoS Pathog (2015) 0.75